SonoVascular, developer of the SonoThrombectomy system for the treatment of venous thromboembolism (VTE), has completed the first close of its US$6 million Series A preferred stock financing.
A press release notes that Harbright Ventures is serving as lead investor, and Robert Ross, founding partner at Harbright, has joined SonoVascular’s board of directors.
The SonoThrombectomy system is an ultrasound-facilitated, thrombolytic-enhanced thrombectomy system that utilises microbubble-mediated cavitation as a core mechanism of action. This system is designed to provide a single-session, standalone cathlab-based procedure.
SonoVascular shares that it has successfully treated 10 patients in South America in its first-in-human (FIH) study for deep vein thrombosis (DVT). Its SonoThrombectomy system achieved a complete 100% Marder score (clot) reduction in all cases as adjudicated by an independent core lab, with no device-related adverse events. Follow-up at both 30 days and six months confirmed significant and sustained improvements from baseline in post-thrombotic syndrome (PTS) severity scores, including Villalta, revised Venous Clinical Severity, and Numeric Pain Rating Scale scores.
According to SonoVascular, the initial results suggest the SonoThrombectomy system has the potential to redefine how clinicians approach clot management, offering a transformative alternative to today’s standard of care.
Lisandro Carnero-Vidal (Clínica La Sagrada Familia, Buenos Aires, Argentina), principal investigator, said: “There is currently no ideal device for the treatment of deep vein thrombosis, as existing technologies carry inherent trade-offs, including blood loss and risk of valvular or endothelial injury. In this first-in-human feasibility study, the SonoThrombectomy system demonstrated a favourable safety profile and consistent procedural performance in patients with deep vein thrombosis. All ten patients were treated successfully, with no device-related serious adverse events and sustained clinical improvement through six-month follow-up. While these findings are preliminary, they support further clinical evaluation of intravascular sonication as a therapeutic approach intended to preserve venous valves and endothelium without blood loss.”
Robert Ross of Harbright Ventures said: “SonoVascular has the rare combination of breakthrough technology and the experienced leadership necessary to redefine the standard of care in VTE. We led this round because SonoVascular is solving the ‘trade-off’ problem that has plagued DVT treatment for years—achieving total clot reduction without the typical risks of blood loss or vessel damage. With exceptionally strong FIH results, we believe this system is well-positioned to become the new standard of care. Equally important, SonoVascular’s solution will ease the burden on ICU [intensive care unit] capacity, saving hospitals and patients time and money.”
SonoVascular states that the Series A round will fund achievement of two important milestones during 2026: (i) secure US Food and Drug Administration (FDA) approval for a US-based peripheral venous pivotal study; and (ii) conduct a FIH study for pulmonary embolism treatment.
